News Releases

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has dosed its first

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share.

SOUTH SAN FRANCISCO, Calif. October 8, 2020 – Aligos Therapeutics, Inc. (Aligos), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company is presenting an e-poster at the virtual

Second drug candidate from Aligos’ CHB portfolio cleared to start first-in-human clinical trial SOUTH SAN FRANCISCO, Calif. September 28, 2020 – Aligos Therapeutics, Inc. (Aligos), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in

SOUTH SAN FRANCISCO, Calif., August 27, 2020 – Aligos Therapeutics, Inc. (Aligos), a private biopharmaceutical  company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, including  chronic hepatitis B (CHB), COVID-19 and therapeutics for NASH, will

SOUTH SAN FRANCISCO, Calif., August 26, 2020 – Aligos Therapeutics, Inc. (Aligos), a private biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B (CHB), COVID-19 and therapeutics for nonalcoholic

Second drug candidate from Aligos’ CHB portfolio advances towards clinical trial   SOUTH SAN FRANCISCO, Calif. August 24, 2020 – Aligos Therapeutics, Inc. (Aligos), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver

First Aligos drug candidate to commence clinical trials First-in-human trial marks ~2.5-year path from company formation to entry into the clinic SOUTH SAN FRANCISCO, Calif. August 18, 2020 – Aligos Therapeutics, Inc. (Aligos), a private clinical stage biopharmaceutical company focused on

SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, July 01, 2020 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Aligos), a private biotechnology company focused on the development of targeted antiviral therapies directed against chronic hepatitis B (CHB), COVID-19 and therapeutics for NASH, today

SOUTH SAN FRANCISCO, Calif., ATLANTA, June 23, 2020 – Aligos Therapeutics, Inc. (Aligos), a private biotechnology company focused on the development of antiviral therapies targeting chronic hepatitis B (CHB) and COVID-19 as well as therapeutics for NASH, announced an expansion to their existing